A new role of miR-29c as a potent inducer of skeletal muscle hypertrophy.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. A 3D skeletal muscle system for disease modelling and secretome profiling of Duchenne muscular dystrophy.Skeletal muscle · 2026
   Article
2. Coding and Noncoding Genes Involved in Atrophy and Compensatory Muscle Growth in Nile Tilapia.Cells · 2022
   Article
3. miR-29c Increases Protein Synthesis in Skeletal Muscle Independently of AKT/mTOR.International journal of molecular sciences · 2022
   Article

Corrections and comments

• Comment on
  miR-29c improves skeletal muscle mass and function throughout myocyte proliferation and differentiation and by repressing atrophy-related genes.2019

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as